Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Leukemia, Myeloid, Acute 69Breast Neoplasms 51Carcinoma, Non-Small-Cell Lung 29Neoplasms 27Myelodysplastic Syndromes 27Advanced Solid Tumors 27Advanced Solid Tumor 26Prostatic Neoplasms 23Stomach Neoplasms 19Recurrence 19Multiple Myeloma 19Neoplasm Metastasis 18Carcinoma, Hepatocellular 17Lung Neoplasms 16Ovarian Neoplasms 15Pancreatic Neoplasms 14Uterine Cervical Neoplasms 13Solid Tumor 13Sarcoma 13Melanoma 13Leukemia, Myelomonocytic, Chronic 13Colorectal Neoplasms 12Triple Negative Breast Neoplasms 10Small Cell Lung Carcinoma 10Lymphoma, Large B-Cell, Diffuse 10Esophageal Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Myeloproliferative Disorders 8Lymphoma, Non-Hodgkin 8Lymphoma, B-Cell 7

Interventions

Doxorubicin 17Ifosfamide 16Radiotherapy 10Filgrastim 5Imatinib Mesylate 4Etoposide 4Chemotherapy, Adjuvant 4pazopanib 3Vincristine 3Neoadjuvant Therapy 3Dactinomycin 3Cyclophosphamide 3Carboplatin 3pegfilgrastim 2cixutumumab 2brostallicin 2belinostat 2Trabectedin 2Sunitinib 2Radiotherapy, Conformal 2Radiation Dose Hypofractionation 2Epirubicin 2Diathermy 2temsirolimus 1soblidotin 1selinexor 1saracatinib 1romidepsin 1ribociclib 1reolysin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Fibrosarcoma × Injections × Clear all
NCT06277154 2025-07-24

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

HRYZ Biotech Co.

Phase 2 Recruiting
148 enrolled
GynecologicSarcoma

Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Endometrial Stromal, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡